Talzenna (Talazoparib Tosylate) Patent Expiration, LOE Window & CMS Spending

Talzenna (Talazoparib Tosylate) by Pfizer: FDA Orange Book core substance LOE 2032-10-16, 0 AB generics, $66.5M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN217439 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-10-16
Last Listed Patent or Exclusivity Date2032-10-16
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$66.5M
2024 Medicare Part D Spend$59.8M
2024 Medicaid Spend$6.7M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 17.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.